J. Schrezenmeier

Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus–Positive Kidney Transplant Recipients

K. Budde, P. Glander, J. Lisec, 2019, Therapeutic drug monitoring.

Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity. A randomized clinical trial

N. Halama, L. Bullinger, M. Addo, 2022, medRxiv.

Endothelial damage and dysfunction in acute graft-versus-host disease

L. Bullinger, M. Díaz-Ricart, Z. Mokhtari, 2020, Haematologica.

Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.

A. Rosenwald, C. Schmitt, L. Bullinger, 2020, Blood.

Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial

N. Halama, L. Bullinger, R. Schlenk, 2022, Nature Cancer.

S282: A RANDOMIZED CONTROLLED CLINICAL TRIAL DEMONSTRATES THAT PLASMA FROM CONVALESCENT AND VACCINATED DONORS IMPROVES OUTCOME OF COVID-19 IN PATIENTS WITH HEMATOLOGICAL DISEASE, CANCER OR IMMUNOSUPPRESSION

N. Halama, R. Schlenk, F. Herth, 2022, HemaSphere.

Initiation of acute graft-versus-host disease by angiogenesis.

C. Schmitt, G. Dittmar, J. Guck, 2016, Blood.